Re-Use of Established Drugs for Anti-Metastatic Indications
Most patients that die from cancer do not die due to the primary tumor but due to the development of metastases. However, there is currently still no drug on the market that specifically addresses and inhibits metastasis formation. This lack was, in the past, largely due to the lack of appropriate s...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2016-01-01
|
Series: | Cells |
Subjects: | |
Online Access: | http://www.mdpi.com/2073-4409/5/1/2 |
id |
doaj-d1dac70d67ca47148b4a527601c17a7c |
---|---|
record_format |
Article |
spelling |
doaj-d1dac70d67ca47148b4a527601c17a7c2020-11-24T23:14:26ZengMDPI AGCells2073-44092016-01-0151210.3390/cells5010002cells5010002Re-Use of Established Drugs for Anti-Metastatic IndicationsFrank Entschladen0Dane A. Thyssen1David W. Drell2MetaVì Labs Inc., 16238 Ranch Road 620 North, Suite F-347, Austin, TX 78717, USAMetaVì Labs Inc., 16238 Ranch Road 620 North, Suite F-347, Austin, TX 78717, USAMetaVì Labs Inc., 16238 Ranch Road 620 North, Suite F-347, Austin, TX 78717, USAMost patients that die from cancer do not die due to the primary tumor but due to the development of metastases. However, there is currently still no drug on the market that specifically addresses and inhibits metastasis formation. This lack was, in the past, largely due to the lack of appropriate screening models, but recent developments have established such models and have provided evidence that tumor cell migration works as a surrogate for metastasis formation. Herein we deliver on several examples a rationale for not only testing novel cancer drugs by use of these screening assays, but also reconsider established drugs even of other fields of indication.http://www.mdpi.com/2073-4409/5/1/2cancermetastasiscell migrationdrug screening |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Frank Entschladen Dane A. Thyssen David W. Drell |
spellingShingle |
Frank Entschladen Dane A. Thyssen David W. Drell Re-Use of Established Drugs for Anti-Metastatic Indications Cells cancer metastasis cell migration drug screening |
author_facet |
Frank Entschladen Dane A. Thyssen David W. Drell |
author_sort |
Frank Entschladen |
title |
Re-Use of Established Drugs for Anti-Metastatic Indications |
title_short |
Re-Use of Established Drugs for Anti-Metastatic Indications |
title_full |
Re-Use of Established Drugs for Anti-Metastatic Indications |
title_fullStr |
Re-Use of Established Drugs for Anti-Metastatic Indications |
title_full_unstemmed |
Re-Use of Established Drugs for Anti-Metastatic Indications |
title_sort |
re-use of established drugs for anti-metastatic indications |
publisher |
MDPI AG |
series |
Cells |
issn |
2073-4409 |
publishDate |
2016-01-01 |
description |
Most patients that die from cancer do not die due to the primary tumor but due to the development of metastases. However, there is currently still no drug on the market that specifically addresses and inhibits metastasis formation. This lack was, in the past, largely due to the lack of appropriate screening models, but recent developments have established such models and have provided evidence that tumor cell migration works as a surrogate for metastasis formation. Herein we deliver on several examples a rationale for not only testing novel cancer drugs by use of these screening assays, but also reconsider established drugs even of other fields of indication. |
topic |
cancer metastasis cell migration drug screening |
url |
http://www.mdpi.com/2073-4409/5/1/2 |
work_keys_str_mv |
AT frankentschladen reuseofestablisheddrugsforantimetastaticindications AT daneathyssen reuseofestablisheddrugsforantimetastaticindications AT davidwdrell reuseofestablisheddrugsforantimetastaticindications |
_version_ |
1725594339530244096 |